Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald assumed coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a note issued to investors on Wednesday. The brokerage set an “overweight” rating and a $25.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 191.38% from the stock’s previous close.

Several other analysts also recently weighed in on ZVRA. JMP Securities initiated coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price on the stock. Roth Mkm upped their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, Guggenheim started coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average price target of $21.57.

Zevra Therapeutics Stock Up 4.1 %

NASDAQ ZVRA traded up $0.34 during trading hours on Wednesday, reaching $8.58. 150,570 shares of the company traded hands, compared to its average volume of 397,903. The company has a 50 day moving average of $8.78 and a two-hundred day moving average of $7.58. The stock has a market capitalization of $457.97 million, a PE ratio of -4.36 and a beta of 2.01. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the company earned ($0.40) EPS. As a group, equities analysts expect that Zevra Therapeutics will post -1.96 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently made changes to their positions in the company. FMR LLC boosted its position in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Zevra Therapeutics in the 3rd quarter valued at approximately $4,858,000. Vestal Point Capital LP bought a new position in Zevra Therapeutics in the third quarter valued at $3,644,000. Propel Bio Management LLC acquired a new position in Zevra Therapeutics during the third quarter valued at approximately $1,248,000. Finally, Geode Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after purchasing an additional 129,600 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.